Kate Schroder

Professor Kate Schroder heads the Inflammasome Laboratory at the Institute for Molecular Bioscience (IMB, UQ), as an NHMRC Leadership Fellow. She is a non-executive Director of the South Australia Health and Medical Research Institute (SAHMRI). Kate trained with Prof Jürg Tschopp, a pioneer in the inflammasome and cell death fields. Upon returning to Australia, Kate established the Inflammasome Lab in 2013. Kate’s laboratory is defining mechanisms of inflammasome signalling, antimicrobial defence and inflammatory disease. Kate’s lab co-invented inflammasome inhibitors entering Phase 2 clinical trials as anti-inflammatory drug candidates, under commercialisation by UQ start-up company, Inflazome, for which Kate served on the Scientific Advisory Board. Inflazome recently sold to pharmaceutical giant Roche for $620M plus milestones, in the largest ever deal for Australian academic intellectual property. Kate regularly serves on Scientific Advisory Boards for biotech start-ups (e.g. Quench USA) and big pharma (e.g. Novartis ATI, Switzerland). Kate is a Clarivate Highly Cited Researcher, having published >140 articles in top journals, and was recently honoured with the 2020 Australian Academy of Science Nancy Millis Medal.